1921
Volume 80, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Cutaneous leishmaniasis caused by () (CL-Lguy) is endemic in the Brazilian Amazon, differing from infection in clinical, diagnostic, and therapeutic aspects. T-cell reactivity to leishmanial antigens possibly involved in the pathogenesis of CL-Lguy was studied herein. Variable lymphoproliferative responses (LPRs) to antigens were found among the 23 studied patients, and 50% of them showed low or no response to these antigens. Active disease was associated with an enrichment of leishmanial-reactive T lymphocytes, mainly TCD4. High and low interferon (IFN)-γ producers were observed. TNF-α, interleukin (IL)-10, and IL-5 were consistently detected. CL-Lguy displayed low antibody response in comparison to patients. CL caused by presented positive LPRs and higher IFN-γ production but undetectable IL-5. seems to induce a down-regulation of the immune system compared with This finding could explain some aspects of clinical presentation of CL-Lguy, such as high tissue parasite burden and frequent resistance to therapy.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2009.80.339
2009-03-01
2017-09-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/80/3/0800339.html?itemId=/content/journals/10.4269/ajtmh.2009.80.339&mimeType=html&fmt=ahah

References

  1. CENEPI, 2002. Fundação Nacional de Saúde (FUNASA). Ministério da Saúde, Guia de Vigilância Epidemiológica, Leishmaniose Tegumentar Americana. Available at: http://www.saude.gov.br/svs. Accessed January 25, 2008.
  2. Grimaldi G Jr, Momen H, Naiff RD, McMahon-Pratt D, 1991. Characterization and classification of leishmanial parasites from humans, wild mammals, and sand flies in the Amazon region of Brazil. Am J Trop Med Hyg 44 : 645–661.
  3. Lainson R, Shaw JJ, Silveira FT, de Souza AA, Braga RR, Ishikawa EAY, 1994. The dermal leishmaniases of Brazil, with special reference to the ecoepidemiology of the disease in Amazonia. Mem Inst Oswaldo Cruz 89 : 435–443.
  4. Romero GA, Guerra MVF, Paes MG, Macêdo VO, 2001. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: clinical findings and diagnostic approach. Clin Infect Dis 32 : 1304–1312.
  5. Guerra JAO, Talhari S, Paes MG, Garrido M, Talhari JM, 2003. Clinical and diagnostic aspects of American tegumentary leishmaniosis in soldiers simulatenously exposed to the infection in the Amazon Region. Rev Soc Bras Med Trop 36 : 587–590.
  6. Naiff RD, Talhari S, Barret TV, 1988. Isolation of Leishmania guyanensis from lesions of the nasal mucosa. Mem Inst Oswaldo Cruz 83 : 529–530.
  7. Romero GA, Ishikawa E, Cupolillo E, Toaldo CB, Guerra MV, Paes GM, Macêdo VO, Shaw JJ, 2002. Identification of antigenically distinct populations of Leishmania (Viannia) guyanensis from Manaus, Brazil, using monoclonal antibodies. Acta Trop 82 : 25–29.
  8. Romero GA, Orge Orge MG, Guerra MVF, Paes MG, Macêdo VO, Carvalho EM, 2005. Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil. Acta Trop 93 : 49–56.
  9. Romero GA, Guerra MV, Paes GM, Macêdo VO, 2001. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 65 : 456–465.
  10. Oliveira-Neto MP, Mattos MS, Perez MA, Da-Cruz AM, Fernandes O, Moreira J, Gonçalves-Costa SC, Brahin LR, Menezes CR, Pirmez C, 2000. American tegumentary leishmaniasis (ATL) in Rio de Janeiro state, Brazil: main clinical and epidemiologic characteristics. Int J Dermatol 39 : 506–514.
  11. Scott P, Artis D, Uzona J, Zaph C, 2004. The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development. Immunol Rev 201 : 318–338.
  12. Saravia NG, Valderrama L, Labrada M, Holguin AF, Navas C, Palma G, Weigle KA, 1989. The relationship of Leishmania braziliensis subspecies and immune response to disease expression in New World leishmaniasis. J Infect Dis 26 : 725–735.
  13. Coutinho SG, Oliveira MP, Da-Cruz AM, De-Luca PM, Mendonça SCF, Bertho AL, Soong L, McMahon-Pratt D, 1996. T-cell responsiveness of American cutaneous leishmaniasis patients to purified Leishmania pifanoi amastigote antigens and Leishmania braziliensis promastigote antigen: immunologic patterns associated with cure. Exp Parasitol 84 : 144–155.
  14. Toledo VPCP, Mayrink W, Gollob KJ, Oliveira MAP, Costa CA, Genaro O, Pinto JA, Afonso LCC, 2001. Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment. Mem Inst Oswaldo Cruz 96 : 89–98.
  15. Bacellar O, Lessa H, Schriefer A, Machado P, Ribeiro de Jesus A, Dutra WO, Gollob KJ, Carvalho EM, 2002. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 70 : 6734–6740.
  16. Bourreau E, Prévot G, Pradinaud R, Launois P, 2001. Interleukin (IL)-13 is the predominant Th2 cytokine in localized cutaneous leishmaniasis lesions and renders specific CD4+ T cells unresponsive to IL-12. J Infect Dis 183 : 953–959.
  17. Bourreau E, Prévot G, Gardon J, Pradinaud R, Launois P, 2001. High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment. J Infect Dis 184 : 1628–1630.
  18. Bourreau E, Collet M, Prévot G, Milon G, Ashimoff D, Hasagewa H, Parra C, Launois P, 2002. IFN- -producing CD45RA+ CD8+ and IL-10-producing CD45RACD4+ T cells generated in response to LACK in naive subjects never exposed to Leishmania. Eur J Immunol 32 : 510–520.
  19. Bourreau E, Gardon J, Pradinaud R, Pascalis H, Prévot G, Kariminia A, Launois P, 2003. Th2 responses predominate during the early phases of infection in patients with localized cutaneous leishmaniasis and precede the development of Th1 responses. Infect Immun 71 : 2244–2246.
  20. Da-Cruz AM, Conceição-Silva F, Bertho AL, Coutinho SG, 1994. Leishmania-reactive CD4+ and CD8+ T cells associated with cure of human cutaneous leishmaniasis. Infect Immun 62 : 2614–2618.
  21. Cupolillo E, Grimaldi G Jr, Momen HA, 1994. A general classification of New World Leishmania using numerical zymotaxonomy. Am J Trop Med Hyg 50 : 296–311.
  22. Towbin H, Stachelin T, Gordon J, 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76 : 4350–4354.
  23. Graham RC, Karnovsky MJ, 1965. The histochemical demonstration of monoamine oxidase activity by coupled peroxidatic oxidation. J Histochem Cytochem 3 : 604–605.
  24. Souza WJS, Coutinho SG, Marzochi MCA, Toledo LM, Gottlieb MV, 1982. Utilização da reação de imunofluorescência indireta no acompanhamento da terapêutica da leishmaniose tegumentar americana. Mem Inst Oswaldo Cruz 77 : 247–253.
  25. Romero GA, Guerra MV, Paes MG, Cupolillo E, Bentin Toaldo C, Macêdo VO, Fernandes O, 2001. Sensitivity of the polymerase chain reaction for the diagnosis of cutaneous leishmaniasis due to Leishmania (Viannia) guyanensis. Acta Trop 79 : 225–229.
  26. Bourreau E, Prévot G, Pradinaud R, Launois P, 2001. Unresponsiveness of specific T cells to IL-12 is associated with active cutaneous leishmaniasis owing to Leishmania guyanensis. Scand J Immunol 54 : 335–339.
  27. Silveira FT, Blackwell JM, Ishikawa EA, Braga R, Shaw JJ, Quinnell RJ, Soong L, Kima P, McMahon-Pratt D, Black GF, Shaw MA, 1998. T cell responses to crude and defined leishmanial antigens in patients from the lower Amazon region of Brazil infected with different species of Leishmania of the subgenera Leishmania and Viannia. Parasite Immunol 20 : 19–26.
  28. Saravia NG, Segura I, Holguin AF, Santrich C, Valderrama L, Ocampo C, 1998. Epidemiologic, genetic, and clinical associations among phenotypically distinct populations of Leishmania (Viannia) in Colombia. Am J Trop Med Hyg 59 : 86–94.
  29. Walker J, Acestor N, Gongora R, Quadroni M, Segura I, Fase N, Saravia NG, 2006. Comparative protein profiling identifies elongation factor-1 and tryparedoxin peroxidase as factor associated with metastasis in L guyanensis. Mol Biochem Parasitol 145 : 254–264.
  30. Da-Cruz AM, Bittar R, Mattos M, Oliveira-Neto MP, Nogueira R, Pinho-Ribeiro V, Azeredo-Coutinho RB, Coutinho SG, 2002. T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy. Clin Diag Lab Immunol 9 : 251–256.
  31. Ghalib HW, Piuvezam MR, Skeiky YA, Sidding M, Hashim FA, el Hassan AM, Russo DM, Reed SG, 1993. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 92 : 324–329.
  32. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA, Sacks DL, 2001. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194 : 1497–1506.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2009.80.339
Loading
/content/journals/10.4269/ajtmh.2009.80.339
Loading

Data & Media loading...

  • Received : 11 Feb 2008
  • Accepted : 20 May 2008

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error